Facilitating Research: Accessing from the Psychiatric Biomarkers Network

The goal of the Psychiatric Biomarkers Network (PBN) is the discovery of robust, replicable, and measurable biological markers to support clinical trials for schizophrenia and bipolar spectrum disorders is to accelerate the discovery, validation, and implementation of biomarkers for neurological disorders. The PBN inventory of biospecimens is available to qualified researchers at both academic and non-academic institutions.

We are continually receiving samples and enrolling new participants. Additionally, data generated using PBN samples are made available along with the clinical data.. We encourage you to visit our website regularly and contact us with any questions about available samples.

Samples Types Available at PBN

Genomic DNA

RNA

Serum

Plasma

PBMCs

CSF

Cell Pellet

We offer a wide range of biospecimens to help answer your most important research questions, and our standardized sample processing protocols and rigorous quality control measures ensure you can trust your results.

Browse all available samples

Navigating the Request Process

Accessing samples from PBN is a straightforward process. From submitting your application to the Biospecimen Review Access Committee (BRAC) to selecting individual samples, our process is designed to support your research needs. Step-by-step guidance is available to assist you through the process.

Learn more about the request process

Affordable Access to Advancement

The Psychiatric Biomarkers Network believes in prioritizing scientific advancement. As part of that commitment, samples are provided at minimal cost for applications approved by the BRAC.

Price Structure

Getting Started

For inquiries, assistance, or to start your research journey with PBN's biospecimens, please contact our dedicated team:

Email: pbnbrac@iu.edu

Stay connected with PBN as we continue to update and expand our repository, contributing to the collective knowledge that fuels progress in schizophrenia and bipolar spectrum disorders research.